Verona Pharma plc, a biotechnology company, is engaged in the research, discovery, and development of therapeutic drugs in the United Kingdom and Canada. The company develops drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma, allergic rhinitis (hay fever), and cough. Its lead drug compound include RPL554, a bronchodilator/anti-inflammatory drug that has completed Phase I and II clinical trials to treat asthma and COPD. The company is also developing VRP700, an anti-tussive drug, which has Phase II clinical trial for the treatment of cough, as well as novel anti-inflammatory polysaccharides (NAIPs) that in the basic research phase to treat respiratory and inflammatory diseases. The company is based in London, the United Kingdom.
verona pharma plc (VNAPF:OTC US)
100 Borough High Street
London, SE1 1LB
Phone: 44 20 7863 3300
Fax: 44 20 7863 3314www.veronapharma.com
|No competitor information is available for VNAPF.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact VERONA PHARMA PLC, please visit www.veronapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.